Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health intends to negotiate a sole source acquisition for X10 vials of Floxuridine 500MG for patient care. This is not a request for proposal, but interested vendors may submit capability statements by June 3, 2026. The acquisition is justified under FAR 6.302-1, citing only one responsible source.
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Cardinal Health dba Specialty Pharmaceutical Services (JND Therapeutics).
Acquisition Description:
The purpose of this acquisition is to purchase X10 VIALS of Floxuridine 500MG vials for injections for patient care.
The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-CC-OLAO-26-006059) by 12:00 PM eastern standard time on 06/03/2026 to: valerie.gregorio@nih.gov.
All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
INTENT TO SOLE SOURCE - X10 VIALS OF FLOXURIDINE 500MG VIALS is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.